Evidence map›Paper›PMID 40924012›Full record

Trial reportAntimicrobial agents and chemotherapy2025

Efficacy and

Nicole E Scangarella-Oman, Deborah L Butler, John Breton, Derrek Brown, Cara Kasapidis, Amanda J Sheets

Abstract readClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Efficacy andAntimicrobial agents and chemotherapy · 2025
    Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nicole E Scangarella-OmanGSK, Collegeville, Pennsylvania, USA.ORCID 0000-0003-4211-8261
Deborah L ButlerGSK, Collegeville, Pennsylvania, USA.
John BretonGSK, Collegeville, Pennsylvania, USA.
Derrek BrownGSK, Collegeville, Pennsylvania, USA.
Cara KasapidisGSK, Collegeville, Pennsylvania, USA.
Amanda J SheetsGSK, Collegeville, Pennsylvania, USA.ORCID 0000-0003-3115-5016

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gepotidacin, a novel, bactericidal, first-in-class triazaacenaphthylene antibacterial, was noninferior to nitrofurantoin in two pivotal trials (EAGLE-2 and EAGLE-3) in females with uncomplicated urinary tract infections (uUTIs). Using pooled data, gepotidacin

Indexed as

AcenaphthenesAnti-Bacterial AgentsHeterocyclic Compounds, 3-RingUrinary Tract Infectionsbeta-LactamasesDNA GyraseDrug Resistance, BacterialEscherichia coliFemaleGenotypeHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsMiddle AgedMutationProteus mirabilisAcenaphthenesAnti-Bacterial Agentsbeta-LactamasesDNA GyrasegepotidacinHeterocyclic Compounds, 3-RingQuinolonesacute cystitisantibacterial resistanceextended-spectrum β-lactamasegenotypegepotidacinmolecular characterizationnitrofurantoinuncomplicated urinary tract infectionuropathogen

Identifiers

PMID40924012
PMCPMC12486806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.